Purchase Order HHSD2002017M94892P
- Not listed
- This federal contract award to Pacific Biosciences of California, Inc. is for the delivery of their Sequel and Sequel II DNA/RNA sequencing platforms, associated reagents, and support services. The $84,000.00 purchase order was issued by the Centers for Disease Control and Prevention (CDC) and does not have a set-aside designation. Pacific Biosciences is the original equipment manufacturer for their proprietary single molecule, real-time (SMRT) sequencing technology. The company has...
- This contract award is to Pacific Biosciences of California, Inc., a for-profit manufacturer, for the delivery of their Sequel and Sequel II DNA/RNA sequencing platforms and associated consumables to the Centers for Disease Control and Prevention (CDC). The $250,000.00 firm-fixed price purchase order has a performance period ending on December 31, 2025. Pacific Biosciences has established itself as a key supplier of specialized sequencing solutions to various federal agencies, as evidenced by...
- This federal contract award to Pacific Biosciences of California, Inc. is for the provision of supplies related to SMRT sequencing technology. The $142,982.42 firm fixed price purchase order was issued by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services and has a period of performance ending on March 31, 2016. Pacific Biosciences is the original equipment manufacturer for their proprietary Sequel and Sequel II DNA/RNA sequencing platforms, which are utilized by...
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm-fixed-price purchase order to Pacific Biosciences of California, Inc., a for-profit manufacturer of specialized scientific equipment, reagents, and services. The $357,500.00 contract is for the provision of Pacific Biosciences' Sequel system, which includes the Sequel DNA/RNA sequencing instrument and associated consumables. The contract has no set-aside designation and is to be performed in...
- This federal contract award to Pacific Biosciences of California, Inc. is for DNA sequencer maintenance services. The $84,000.00 firm-fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) in Pittsburgh, Pennsylvania, a civilian agency. The contract has an ultimate completion date of January 13, 2019 and was awarded on January 14, 2018. Pacific Biosciences, a for-profit manufacturer, was selected without a set-aside designation, indicating they are the...
- This is a firm-fixed price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Pacific Biosciences of California, Inc. for $84,000.00. The contract is for a service plan and has no set-aside designation. Pacific Biosciences is the original equipment manufacturer for their proprietary single molecule, real-time (SMRT) DNA/RNA sequencing technology. This contract award is likely part of Pacific Biosciences' broader work providing specialized sequencing...
- This is a firm-fixed price contract award to Pacific Biosciences of California, Inc. by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services. The $105,940 contract is for the provision of PacBio reagents, which are used in Pacific Biosciences' proprietary Sequel and Sequel II DNA/RNA sequencing platforms. These specialized sequencing systems and associated consumables are utilized by various federal civilian and defense agencies to support genomic research...
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $193,000.00 firm fixed price purchase order to Pacific Biosciences of California, Inc. to upgrade their PacBio Sequel System. This contract does not have a set-aside designation. Pacific Biosciences is a manufacturer of specialized scientific equipment, reagents, and services associated with their Sequel and Sequel II DNA/RNA sequencing systems. They have fulfilled over $10 million in federal...
- This contract is a Blanket Purchase Agreement (BPA) call awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to Pacific Biosciences of California, Inc., a manufacturer of specialized scientific equipment, reagents, and services associated with their Sequel and Sequel II DNA/RNA sequencing systems. The contract has a potential value of $168,880.71 and is for the delivery of sequencing instruments, consumables, and associated services to support...
- This contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to Pacific Biosciences of California, Inc. for laboratory equipment maintenance services for the agency's PacBio RSII and Sequel DNA sequencing systems. The $119,000 firm fixed-price purchase order has a completion date of September 18, 2020. Pacific Biosciences is a manufacturer of specialized scientific equipment, reagents, and sequencing services that has fulfilled over $10...
This federal contract award, valued at $84,000.00, was issued by the Centers for Disease Control and Prevention (CDC) to Pacific Biosciences of California, Inc. for a service agreement related to their Pacific Biosciences RS DNA Sequencer. The contract is a firm fixed-price purchase order without a set-aside designation. Pacific Biosciences is the original equipment manufacturer of the Sequel and Sequel II DNA/RNA sequencing platforms, which are utilized by various federal agencies to support genomic research initiatives. This contract provides the CDC with access to Pacific Biosciences' specialized sequencing systems, consumables, and associated services. The company has established itself as a key supplier of long-read sequencing solutions to federal civilian and defense agencies, holding multiple Indefinite Delivery Indefinite Quantity (IDIQ) contract vehicles, including a $13.5 million IDIQ with the USDA Agricultural Research Service and a $1 million IDIQ with the FDA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $84.0k | 7/28/17 |